• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23368 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2018     Andalusian Health Technology Assessment Area (AETSA) [Epigenetic profile for the identification of primary cancer of unknown origin]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (rheumatoid arthritis) - Addendum to Commission A18-28]
2018     National Institute for Health and Care Excellence (NICE) Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer. NICE technology appraisal guidance 509
2018     National Institute for Health and Care Excellence (NICE) Aortic valve reconstruction with processed bovine pericardium. NICE interventional procedures guidance 604
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) High-intensity focused ultrasound for the treatment of prostate cancer. 1st Update 2018
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Brodalumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 511
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) (Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation. 3rd Update 2018
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Tenofovir alafenamide in patients with HIV diagnosis]
2018     Andalusian Health Technology Assessment Area (AETSA) [Point of care test for differential diagnosis of virus versus bacteria in acute respiratory tract infection]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Interstitial low-dose-rate brachytherapy for localized prostate cancer - rapid report]
2018     National Institute for Health and Care Excellence (NICE) Tivozanib for treating advanced renal cell carcinoma. NICE technology appraisal guidance 512
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Subcutaneous implantable cardioverter defibrillator (ICD)
2018     Andalusian Health Technology Assessment Area (AETSA) [Cardiopoietic stem cells for the treatment of heart failure secondary to myocardial ischemia]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Synchronous balneo-phototherapy for atopic eczema - rapid report]
2018     National Institute for Health and Care Excellence (NICE) Obinutuzumab for untreated advanced follicular lymphoma. NICE technology appraisal guidance 513
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Lymphovenous anastomoses in patients with primary and secondary lymphoedema
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Osimertinib in lung cancer]
2018     Andalusian Health Technology Assessment Area (AETSA) [Health technology assessment network in the SSPA. Methodology and work procedures]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Brivaracetam (epilepsy) - Benefit assessment in accordance with §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen. NICE technology appraisal guidance 515
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Allogeneic mesenchymal stem cells for Crohn’s disease-associated complex perianal fistulas
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of clinical data from electronic medical records for research and continuous quality improvement in front-line care and services]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Montelukast in patients with chronic allergic rhinitis and no asthma]
2018     Andalusian Health Technology Assessment Area (AETSA) [Clinical practice guidelines on severe mental disorder]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment switching in oncological studies]
2018     National Institute for Health and Care Excellence (NICE) Cabozantinib for treating medullary thyroid cancer. NICE technology appraisal guidance 516
2018     NIHR Health Technology Assessment programme Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT
2018     NIHR Health Technology Assessment programme Options for possible changes to the blood donation service: health economics modelling
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Meniscal allograft transplantation for post-meniscectomy syndrome
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Mechanical devices for urinary incontinence]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cabozantinib (renal cell carcinoma) - Addendum to Commission A18-37]
2018     National Institute for Health and Care Excellence (NICE) Avelumab for treating metastatic Merkel cell carcinoma. NICE technology appraisal guidance 517
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnosis and treatments for epilepsy – a systematic review]
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Baroreceptor activation therapy for treatment-resistant hypertension
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Ketogenic diet for refractory epilepsy]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Gemtuzumab ozogamicin (acute myeloid leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Tocilizumab for treating giant cell arteritis. NICE technology appraisal guidance 518
2018     NIHR Health Technology Assessment programme The Patient Centred Assessment Method for improving nurse-led biopsychosocial assessment of patients with long-term conditions: a feasibility RCT
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Hyperbaric oxygen therapy in pseudoarthrosis]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 520
2018     NIHR Health Technology Assessment programme Multiple-frequency bioimpedance devices for fluid management in people with chronic kidney disease receiving dialysis: a systematic review and economic evaluation
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Bone marrow stem cell therapy for orthopedic conditions]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bosutinib (pretreated chronic myelogenous leukaemia) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Guselkumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 521
2018     NIHR Health Technology Assessment programme Self-care support for children and adolescents with long-term conditions: the REfOCUS evidence synthesis
2018     NIHR Health Technology Assessment programme Therapy interventions for children with neurodisabilities: a qualitative scoping study
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)
2018     Institut national d'excellence en sante et en services sociaux (INESSS) [Flashglucose monitoring system (Freestyle Libre, Abbott), report updated April 8 2020]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tofacitinib (Colitis) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Midostaurin for untreated acute myeloid leukaemia. NICE technology appraisal guidance 523
2018     NIHR Health Technology Assessment programme Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) External stimulation of the trigeminal nerve for the prevention and acute treatment of episodic and chronic migraine
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma. NICE technology appraisal guidance 524
2018     NIHR Health Technology Assessment programme The West Midlands ActiVe lifestyle and healthy Eating in School children (WAVES) study: a cluster randomised controlled trial testing the clinical effectiveness and cost-effectiveness of a multifaceted obesity prevention intervention programme targeted at children aged 6-7 years
2018     NIHR Health Services and Delivery Research programme Understanding employee whistleblowing in health care
2018     NIHR Health Technology Assessment programme The West Midlands ActiVe lifestyle and healthy Eating in School children (WAVES) study: a cluster randomised controlled trial testing the clinical effectiveness and cost-effectiveness of a multifaceted obesity prevention intervention programme targeted at children aged 6-7 years
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) PET/PET-CT Evidence for need based planning in Germany and Austria
2018     Penn Medicine Center for Evidence-based Practice (CEP) Testing for clostridium difficile in oncology patients
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ingenol mebutate (actinic keratosis) - Benefit assessment according to §35a Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 525
2018     NIHR Health Services and Delivery Research programme A meta-ethnography of healthcare professionals' experience of treating adults with chronic non-malignant pain to improve the experience and quality of healthcare
2018     NIHR Health Technology Assessment programme Computerised interpretation of the fetal heart rate during labour: a randomised controlled trial (INFANT)
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Supporting children who have parents with mental disorders in Tyrol: A mapping of existing Tyrolean support and societal structures
2018     Penn Medicine Center for Evidence-based Practice (CEP) Securement of Arterial Catheters
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Pertuzumab (breast cancer) - Addendum to Commission A18-41]
2018     National Institute for Health and Care Excellence (NICE) Arsenic trioxide for treating acute promyelocytic leukaemia. NICE technology appraisal guidance 526
2018     NIHR Health Services and Delivery Research programme Predictive risk stratification model: a randomised stepped-wedge trial in primary care (PRISMATIC)
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance
2018     Penn Medicine Center for Evidence-based Practice (CEP) Guidance for Prostate Cancer Screening
2018     National Institute for Health and Care Excellence (NICE) Beta interferons and glatiramer acetate for treating multiple sclerosis. NICE technology appraisal guidance 527
2018     NIHR Health Technology Assessment programme Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT
2018     NIHR Health Technology Assessment programme Advantages and limitations of virtual online consultations in a NHS acute trust: the VOCAL mixed-methods study
2018     NIHR Health Services and Delivery Research programme Clinical leadership in service redesign using Clinical Commissioning Groups: a mixed-methods study
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Inhalation sedation with laughing gas (N2O) in dentistry – organisational and professional aspects and a systematic review of efficacy and safety
2018     Penn Medicine Center for Evidence-based Practice (CEP) Risk Factors for Surgical Site Infection and Infection Prevention in Elective Spine Surgery
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Bictegravir/emtricitabine/tenofovir alafenamide (HIV infection) - Addendum to Commission A18-43]
2018     National Institute for Health and Care Excellence (NICE) Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 529
2018     NIHR Health Technology Assessment programme Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT
2018     NIHR Public Health Research (PHR) programme Cluster randomised controlled trial and economic and process evaluation to determine the effectiveness and cost effectiveness of a novel intervention [Healthy Lifestyles Programme (HeLP)] to prevent obesity in school children
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Drug reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process, taking into account international experience
2018     Penn Medicine Center for Evidence-based Practice (CEP) Venous Thromboembolism Prevention for Obese Patients
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for serological group B streptococci within the framework of the medical check-ups according to the maternity Guidelines]
2018     National Institute for Health and Care Excellence (NICE) Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy. NICE technology appraisal guidance 530
2018     NIHR Public Health Research (PHR) programme Collaborative case management to aid return to work after long-term sickness absence: a pilot randomised controlled trial
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)
2018     Penn Medicine Center for Evidence-based Practice (CEP) Scales for Assessing Patients Receiving Moderate Sedation
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (B-cell acute lymphoblastic leukaemia) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer. NICE technology appraisal guidance 531
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström’s macroglobulinaemia
2018     Penn Medicine Center for Evidence-based Practice (CEP) The Effect of Electronic Medical Record Alerts on Provider Wellness
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2018     Agency for Healthcare Research and Quality (AHRQ) Attention deficit hyperactivity disorder: diagnosis and treatment in children and adolescents
2018     National Institute for Health and Care Excellence (NICE) Ocrelizumab for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 533
2018     NIHR Health Technology Assessment programme Lamotrigine for people with borderline personality disorder: a RCT
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk. Update 2018